ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY

Authors :: Paul W. Armstrong
Matthew T. Roe
Cynthia M. Westerhout
Yinggan Zheng
Darren K. McGuire
Jay Shavadia
Eric D. Peterson
Jennifer B. Green
Jan H. Cornel
Rury R. Holman
Source :: Journal of the American College of Cardiology. 73:138
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.
Abstract: The secondary prevention effects of beta-blocker therapy (BBT) in type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) are unclear. Using an inverse probability of treatment-weighted Cox proportional hazards model, we examined the association between baseline BBT and

Subjects :: Secondary prevention
medicine.medical_specialty
Proportional hazards model
Atherosclerotic cardiovascular disease
Beta blocker therapy
business.industry
Type 2 diabetes
medicine.disease
Diabetes mellitus
Internal medicine
medicine
In patient
Cardiology and Cardiovascular Medicine
business
Cardiovascular outcomes

Tools